BioGend Therapeutics , Ltd. Overview
Latest ROE for BioGend Therapeutics , Ltd.: -6.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-6.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 6733.TWO is -6.59%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside BioGend Therapeutics , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 6733.TWO currently prints -6.59% for ROE, while the sector average sits near -100.59%. That is roughly 93.4% above the sector mean. Large gaps often invite a closer look at BioGend Therapeutics , Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively BioGend Therapeutics , Ltd. converts resources into returns. At -6.59%, 6733.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 6733.TWO's ROE (-6.59%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack BioGend Therapeutics , Ltd.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
